Previous 10 | Next 10 |
2024-01-25 15:30:27 ET Summary Vera Therapeutics, Inc. stock price soared over 35% today as it announced positive results from the open label extension of its Phase 2b ORIGIN clinical trial for atacicept in IgA nephropathy. The company's stock is up over 160% in the past year and ...
2024-01-08 12:21:42 ET More on Travere Therapeutics Travere to seek FDA approval for Filspari in IgAN but not FSGS Travere Therapeutics Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Travere Therapeutics Historical earnings data for Travere T...
Received 459 new patient start forms for FILSPARI ® (sparsentan) in the fourth quarter of 2023; preliminary net product sales of FILSPARI totaled $15 million for the fourth quarter Company on track to submit sNDA to FDA in Q1 2024 for conversion of the existing U.S. acc...
SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 3:45 p.m. PT. A live we...
2023-12-28 10:55:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...
2023-12-19 09:10:24 ET Summary Mirum Pharmaceuticals, Inc. stock dropped 16% after its lead asset, Livmarli, failed to meet primary or secondary endpoints in a phase 2 trial for biliary atresia. This looks like an overreaction considering the small addressable market and no negati...
2023-12-16 04:30:00 ET Summary The Russell 2000 is experiencing an earnings recession, with negative growth expected to continue into Q4. Q3 earnings season saw a positive surprise, with blended earnings growth improving by 430 bps to -9.9% y/y. Earnings and revenue momentum l...
SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has opened enrollment in the HARMONY Study, a global, randomized pivotal Phase 3 clinical trial of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated f...
2023-12-07 17:09:39 ET Gainers: Grayscale Solana Trust ( OTCQB:GSOL ) +7% . Accolade ( ACCD ) +5% . TPI Composites ( TPIC ) +5% . Travere Therapeutics ( TVTX ) +4% . 1-800-FLOWERS ( FLWS ) +3% . Losers: HashiCorp ( HCP ...
News, Short Squeeze, Breakout and More Instantly...
Travere Therapeutics Inc Com Company Name:
TVTX Stock Symbol:
NASDAQ Market:
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on May 10, 2024, the Compensation Co...
2024-05-14 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Presentations highlight data supporting FILSPARI® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly d...